BROOKLYN, N.Y., June 05, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc.(NASDAQ:AZRX) (“AzurRx” or the “Company”), a company
specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company
will be making a company presentation at two upcoming investor conferences: the LD Micro Invitational conference in Los Angeles
at the Luxe Sunset Boulevard Hotel, on Tuesday, June 6th at 5:00 p.m. PST and at the 2017 Marcum
MicroCap Conference in New York City at the Grand Hyatt Hotel on Thursday, June 15th at 4:30 P.M. EST.
About AzurRx BioPharma, Inc.:
AzurRx BioPharma, Inc. (NASDAQ:AZRX) is engaged in the research and development of non-systemic biologics for the treatment of
patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the Company's lead
development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections. The
Company is headquartered in Brooklyn, NY, with scientific operations based in Langlade, France. Additional information on the
company can be found at www.azurrx.com.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigations Reform Act of 1995.
Such statements include, but are not limited to, any statements relating to our product development programs and any other
statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from
management's current expectations include those risks and uncertainties relating to the development and testing of our drug
candidates, the regulatory approval process, our ability to secure additional financing, the protection of our patent and
intellectual property, the success of strategic agreements and relationships, and the potential commercialization of any product we
may successfully develop. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to
any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as required by law.
CONTACT: AzurRx BioPharma, Inc. 760 Parkside Avenue, Suite 304 Brooklyn, NY 11226 Phone: 646.699.7855 www.azurrx.com info@azurrx.com
